

## HR 1223

### OPEN Act

**Congress:** 115 (2017–2019, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Feb 27, 2017

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Mar 3, 2017)

**Official Text:** <https://www.congress.gov/bill/115th-congress/house-bill/1223>

### Sponsor

---

**Name:** Rep. Bilirakis, Gus M. [R-FL-12]

**Party:** Republican • **State:** FL • **Chamber:** House

## Cosponsors (43 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Butterfield, G. K. [D-NC-1]	D · NC		Feb 27, 2017
Rep. McCaul, Michael T. [R-TX-10]	R · TX		Feb 27, 2017
Rep. Frelinghuysen, Rodney P. [R-NJ-11]	R · NJ		Mar 1, 2017
Rep. Lance, Leonard [R-NJ-7]	R · NJ		Mar 1, 2017
Rep. Soto, Darren [D-FL-9]	D · FL		Mar 1, 2017
Rep. Donovan, Daniel M., Jr. [R-NY-11]	R · NY		Mar 8, 2017
Rep. Eshoo, Anna G. [D-CA-18]	D · CA		Mar 8, 2017
Rep. Murphy, Tim [R-PA-18]	R · PA		Mar 8, 2017
Rep. Mullin, Markwayne [R-OK-2]	R · OK		Mar 16, 2017
Rep. Norcross, Donald [D-NJ-1]	D · NJ		Mar 16, 2017
Rep. Fortenberry, Jeff [R-NE-1]	R · NE		Mar 24, 2017
Rep. Huffman, Jared [D-CA-2]	D · CA		Mar 24, 2017
Rep. Bacon, Don [R-NE-2]	R · NE		Apr 3, 2017
Rep. Webster, Daniel [R-FL-11]	R · FL		Apr 3, 2017
Rep. Palazzo, Steven M. [R-MS-4]	R · MS		May 22, 2017
Rep. Rooney, Francis [R-FL-19]	R · FL		Jun 12, 2017
Rep. Lofgren, Zoe [D-CA-19]	D · CA		Jun 23, 2017
Rep. McMorris Rodgers, Cathy [R-WA-5]	R · WA		Jun 27, 2017
Rep. Sires, Albio [D-NJ-8]	D · NJ		Jun 28, 2017
Rep. Swalwell, Eric [D-CA-15]	D · CA		Jun 28, 2017
Rep. Upton, Fred [R-MI-6]	R · MI		Jul 11, 2017
Rep. Olson, Pete [R-TX-22]	R · TX		Jul 12, 2017
Rep. Long, Billy [R-MO-7]	R · MO		Jul 28, 2017
Rep. Brooks, Mo [R-AL-5]	R · AL		Sep 5, 2017
Rep. Shea-Porter, Carol [D-NH-1]	D · NH		Sep 5, 2017
Rep. Stivers, Steve [R-OH-15]	R · OH		Sep 13, 2017
Rep. Clay, Wm. Lacy [D-MO-1]	D · MO		Oct 11, 2017
Rep. Comstock, Barbara [R-VA-10]	R · VA		Mar 5, 2018
Rep. Fitzpatrick, Brian K. [R-PA-8]	R · PA		Mar 5, 2018
Rep. Hastings, Alcee L. [D-FL-20]	D · FL		Mar 5, 2018
Rep. Smith, Christopher H. [R-NJ-4]	R · NJ		Mar 5, 2018
Rep. Lujan Grisham, Michelle [D-NM-1]	D · NM		Mar 6, 2018
Rep. Young, David [R-IA-3]	R · IA		Apr 10, 2018
Rep. Culberson, John Abney [R-TX-7]	R · TX		May 1, 2018
Rep. Rice, Kathleen M. [D-NY-4]	D · NY		Jun 12, 2018
Rep. Watson Coleman, Bonnie [D-NJ-12]	D · NJ		Jun 19, 2018
Rep. Visclosky, Peter J. [D-IN-1]	D · IN		Jul 17, 2018
Rep. Reichert, David G. [R-WA-8]	R · WA		Jul 31, 2018
Rep. Messer, Luke [R-IN-6]	R · IN		Aug 28, 2018
Rep. Posey, Bill [R-FL-8]	R · FL		Aug 28, 2018
Rep. Roskam, Peter J. [R-IL-6]	R · IL		Aug 31, 2018

Cosponsor	Party / State	Role	Date Joined
Rep. Poe, Ted [R-TX-2]	R · TX		Sep 4, 2018
Rep. Price, David E. [D-NC-4]	D · NC		Oct 16, 2018

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 3, 2017

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
115 S 1509	Related bill	Jun 29, 2017: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

## Summary (as of Feb 27, 2017)

### Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017 or the OPEN Act

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Department of Health and Human Services (HHS) to extend by six months the exclusivity period for a drug or biological product approved by the Food and Drug Administration (FDA) when the product is additionally approved to prevent, diagnose, or treat a new indication that is a rare disease or condition (also known as an orphan disease).

HHS may revoke an extension if the application submitted to the FDA for the new indication contained an untrue material statement.

HHS must notify the public of products that receive this extension and patents related to those products.

Products may receive only one extension under this bill. Extensions under this bill are in addition to other extensions. The bill applies only to products approved after enactment of this bill for a new indication that is a rare disease or condition.

## Actions Timeline

- **Mar 3, 2017:** Referred to the Subcommittee on Health.
- **Feb 27, 2017:** Introduced in House
- **Feb 27, 2017:** Referred to the House Committee on Energy and Commerce.